Search
Rituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalIt was originally approved by the U.S. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].
Categories: CHOP-R chemotherapy regimenProducts: TRUXİMA 500 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, MABTHERA 100 MG/10 ML IV INFUZYON İÇİN KONSANTRE ÇÖZELTİ İÇEREN FLAKON, 2 ADETUmeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigational[A7719] However, even though umeclidinium monotherapy is well-tolerated for up to 14 days, it is more likely to be used in combination therapy, as the international Gold Initiative for Chronic Obstructive … [A7719] By blocking the M3 muscarinic receptor, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction.
Mixtures: ANORO ELLIPTA 62.5 MCG + 25 MCG KULLANIMA HAZIR INHALASYON TOZU, 3 X 30 DOZCategories: Agents to Treat Airway Disease, Cytochrome P-450 SubstratesGanaxolone
go.drugbank.com/drugs/DB05087ApprovedInvestigational[L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesRemestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawn[L11022] Remestemcel-L was later approved by the FDA on December 18, 2024. … It is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022].
Synonyms: Remestemcel-LCrizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigational[A250785] Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.[L42460] … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: (R)-crizotinibGuanoxan
go.drugbank.com/drugs/DB13211ApprovedGuanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.
Belantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawnUS marketing authorization in November 2022. … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.
Categories: P-glycoprotein substratesTestosterone undecanoate
go.drugbank.com/drugs/DB13946ApprovedInvestigational[L35970] It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone. … Male hypogonadism, resulting from insufficient testosterone secretion, can result symptoms and signs of testosterone deficiency, such as decreased libido, erectile dysfunction, and loss of muscle and bone
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: NEBIDO 250 MG/ML IM ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET, UROMAX® 1000MG/4 ML SOLUCIÓNINYECTABLECorticosterone Methyl Oxidase I Deficiency (CMO I)
smpdb.ca/view/SMP0000577DiseaseCorticosterone methyloxidase type I (CMO-I) deficiency, also known as 18-hydroxylase deficiency or aldosterone deficiency among other names, is a genetic disorder that is autosomally linked and caused … In CMO-I deficiency, aldosterone levels are so low that they are undetectable in plasma.